Hematology
Advertisement
MDS experts tell of the clinical factors they consider when selecting from the available agent options.
An MDS expert panel discusses findings from the trial's comparison of luspatercept with ESAs in this setting.
Mairéad Ní Chonghaile, RGN, BNS, MSc, speaks on the need for training and support networks in this area of care.
Phase II study data demonstrate this benefit in patients with low-risk myeloid malignancies or precursor conditions.
Final data from a phase II trial suggest a promising option for elderly patients with this serious disease.
Dr. Chedid brings an update highlighting the most noteworthy recent findings from MDS clinical trials.
Results from a new analysis further support the initial findings of the global, phase III IMerge trial.
A systematic review found IV administration to have fewer postoperative complications and better quality of life.
Quality of life improvement is among the benefits from this agent in patients with congenital disease.
In PNH not previously treated with C5 inhibitors, crovalimab has shown efficacy noninferior to eculizumab.
An ongoing phase IIA study reports safety and dosing data for patients with transfusion-dependent disease.
A retrospective observational study's clearest takeaway was that the agent can reduce spontaneous bleeding in severe disease.
This noninvasive technique is a potential improvement over bone marrow aspiration in MDS clinical evaluation and monitoring.
Myeloablation followed by exa-cel infusion brought transfusion independence to β-thalassemia patients in a phase III trial.
Kristen Howell, PhD, MPH, has investigated how transfer gaps in SCD care affect patients as they transition to adult care.
Dr. Restrepo discusses coagulation and issues in coagulopathy risk screening in patients who have venous malformations.
Aspirin was found to be safe and effective in patients with a wide range of VTE risk who underwent total knee arthroplasty.
Konstanze Döhner, MD, met to discuss the background and ongoing progress of the EHA Lighting the Flame program.
These proof-of-concept data may spur further studies toward developing a single-intervention cure for patients.
Before performing allogeneic HSCT in AA patients, clinicians should measure ANC as a prognostic factor.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.